BioCentury
ARTICLE | Distillery Therapeutics

Cancer

July 10, 2017 6:04 PM UTC

Cell culture studies identified a compound that recruits androgen receptor to IAP for proteasomal degradation that could help treat prostate cancer. The compound consisted of an androgen receptor ligand and a peptidomimetic of the IAP ligand DIABLO joined by a polyethylene glycol (PEG) linker. In two androgen receptor-dependent human prostate cancer cell lines, a 3 μM dose of the compound decreased androgen receptor levels to about 50% of baseline levels within 4 hours. In an androgen receptor-dependent human prostate cancer cell line, the compound decreased proliferation and increased apoptosis compared with the androgen receptor antagonist Casodex bicalutamide. Next steps include developing more potent versions of the compound.

AstraZeneca plc markets Casodex to treat prostate cancer...